DOCS vs. KRYS, MDGL, MMSI, NUVL, CRSP, IMVT, HAE, SEM, ALPN, and TMDX
Should you be buying Doximity stock or one of its competitors? The main competitors of Doximity include Krystal Biotech (KRYS), Madrigal Pharmaceuticals (MDGL), Merit Medical Systems (MMSI), Nuvalent (NUVL), CRISPR Therapeutics (CRSP), Immunovant (IMVT), Haemonetics (HAE), Select Medical (SEM), Alpine Immune Sciences (ALPN), and TransMedics Group (TMDX). These companies are all part of the "medical" sector.
Krystal Biotech (NASDAQ:KRYS) and Doximity (NASDAQ:DOCS) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 87.2% of Doximity shares are held by institutional investors. 14.1% of Krystal Biotech shares are held by insiders. Comparatively, 39.4% of Doximity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Doximity has a net margin of 29.39% compared to Doximity's net margin of 0.00%. Krystal Biotech's return on equity of 16.08% beat Doximity's return on equity.
In the previous week, Krystal Biotech had 25 more articles in the media than Doximity. MarketBeat recorded 33 mentions for Krystal Biotech and 8 mentions for Doximity. Doximity's average media sentiment score of 0.58 beat Krystal Biotech's score of 0.39 indicating that Krystal Biotech is being referred to more favorably in the media.
Doximity has higher revenue and earnings than Krystal Biotech. Doximity is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Krystal Biotech has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Doximity has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
Krystal Biotech received 229 more outperform votes than Doximity when rated by MarketBeat users. Likewise, 66.83% of users gave Krystal Biotech an outperform vote while only 41.53% of users gave Doximity an outperform vote.
Krystal Biotech presently has a consensus target price of $171.00, indicating a potential upside of 10.45%. Doximity has a consensus target price of $28.82, indicating a potential upside of 25.30%. Given Krystal Biotech's higher possible upside, analysts plainly believe Doximity is more favorable than Krystal Biotech.
Summary
Krystal Biotech and Doximity tied by winning 9 of the 18 factors compared between the two stocks.
Get Doximity News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Doximity Competitors List
Related Companies and Tools
